# Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

> **NCT01719549** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01719549
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2016-02
- **Final completion:** 2016-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01719549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01719549, "Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01719549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*